{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:20:21Z","timestamp":1787566821597,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002825","name":"Dystrophic Epidermolysis Bullosa Research Association of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.eclinm.2026.104103","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:09:40Z","timestamp":1785143380000},"page":"104103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0637-472X","authenticated-orcid":false,"given":"Fatima","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-8332","authenticated-orcid":false,"given":"Alison K.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Graier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8742-5401","authenticated-orcid":false,"given":"Mahira","family":"El Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9133-2008","authenticated-orcid":false,"given":"Rachel H.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5303-9310","authenticated-orcid":false,"given":"Jo","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4629-1486","authenticated-orcid":false,"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-1115","authenticated-orcid":false,"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2958-915X","authenticated-orcid":false,"given":"Darren M.","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0084-3131","authenticated-orcid":false,"given":"Peter","family":"C.M. van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-4427","authenticated-orcid":false,"given":"Christopher E.M.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-056X","authenticated-orcid":false,"given":"Sean P.","family":"Gavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-3675","authenticated-orcid":false,"given":"Su Mar","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10281","key":"10.1016\/j.eclinm.2026.104103_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104103_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1518681","article-title":"Dynamic trend analysis of global psoriasis burden from 1990 to 2021: a study of gender, age, and regional differences based on GBD 2021 data","volume":"13","author":"Xiong","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.eclinm.2026.104103_bib3","series-title":"Explore the data","year":"2025"},{"key":"10.1016\/j.eclinm.2026.104103_bib4","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104103_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307234","article-title":"Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: a Malaysian healthcare system perspective","volume":"19","author":"Azizam","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104103_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/bjd\/ljac128","article-title":"Access to psoriasis treatment in Brazil and Chile: a cross-sectional multicentre Global Healthcare Study on Psoriasis","volume":"188","author":"Maul","year":"2023","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104103_bib7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ijd.17236","article-title":"Disparities and barriers to the access of biologics in moderate-to-severe adult psoriasis","volume":"63","author":"Wan","year":"2024","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104103_bib8","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s13555-023-01014-x","article-title":"Increasing access to effective systemic treatments in patients with moderate-to-severe psoriasis: narrative review","volume":"13","author":"Girolomoni","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.eclinm.2026.104103_bib9","series-title":"The selection and use of essential medicines, 2025 report of the 25th WHO expert committee on selection and use of essential medicines, executive summary","year":"2025"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104103_bib10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jamadermatol.2023.1338","article-title":"Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies","volume":"159","author":"Phan","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104103_bib11","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","article-title":"Drug persistence of biologic treatments in psoriasis: a Swedish national population study","volume":"11","author":"Schmitt-Egenolf","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.eclinm.2026.104103_bib12","series-title":"Cost-effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104103_bib13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/jamadermatol.2017.2103","article-title":"Psoriasis","volume":"153","author":"Armstrong","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104103_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/1346-8138.17049","article-title":"Pediatric psoriasis: understanding pathological conditions and advances in treatment","volume":"51","author":"Morita","year":"2023","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104103_bib15","first-page":"1091","article-title":"Global burden of psoriasis in children and adolescents, 1990\u20132021: a population-based study","volume":"21","author":"Zhang","year":"2025","journal-title":"Arch Med Sci"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104103_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/ijpd.IJPD_76_16","article-title":"Clinicoepidemiological study of childhood psoriasis in a tertiary care center","volume":"18","author":"Suganya","year":"2017","journal-title":"Indian J Paediatr Dermatol"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104103_bib17","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study","volume":"62","author":"Tollefson","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104103_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ad.2018.10.015","article-title":"Epidemiology of psoriasis. A population-based study","volume":"110","author":"Fern\u00e1ndez-Armenteros","year":"2019","journal-title":"Actas Dermosifiliogr"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104103_bib19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.eclinm.2026.104103_bib20","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1038\/jid.2015.296","article-title":"Psoriasis in the U.S. medicare population: prevalence, treatment, and factors associated with biologic use","volume":"135","author":"Takeshita","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104103_bib21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/TCRM.S2740","article-title":"Moderate and severe plaque psoriasis: cost-of-illness study in Italy","volume":"4","author":"Colombo","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104103_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.eclinm.2026.104103_bib23","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"2023","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/1744666X.2023.2141226","article-title":"Tailored biological treatment for patients with moderate-to-severe psoriasis","volume":"19","author":"Maurelli","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.eclinm.2026.104103_bib25","first-page":"117","article-title":"Psoriasis: prevalence, clinical variants and quality of life, among patients attending the skin clinic at Mbarara regional referral hospital, Uganda. Psoriasis","volume":"15","author":"Lubwama","year":"2025","journal-title":"Targets Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20204934","article-title":"A clinico-epidemiological study of psoriasis patients with moderate to severe plaque type in tertiary care centre in South India","volume":"7","author":"Sekar","year":"2021","journal-title":"Int J Res Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104103_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/idoj.idoj_350_23","article-title":"Patient perspectives of the impact of psoriatic disease on quality-of-life in India: sub-analysis from the Global Psoriasis and Beyond Survey","volume":"15","author":"Chandrashekar","year":"2024","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/24755303241302070","article-title":"Criteria for identifying candidates for systemic psoriasis treatment in the real world: application of the International Psoriasis Council guidelines in patients in North America","volume":"10","author":"Strober","year":"2024","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104103_bib29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijd.16652","article-title":"Drug survival of methotrexate and predictor factors for discontinuation in psoriasis","volume":"62","author":"Caldarola","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.eclinm.2026.104103_bib30","series-title":"Countries data","year":"2025"},{"key":"10.1016\/j.eclinm.2026.104103_bib31","article-title":"Monoclonal antibodies and Fc-fusion protein biologic medicines: a multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020","volume":"26","author":"Tong","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/srt.13550","article-title":"Use of biologics in patients with psoriasis \u2013 a retrospective analysis based on real-world data","volume":"30","author":"Pan","year":"2024","journal-title":"Skin Res Technol"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104103_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237267","article-title":"Patients\u2019 demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis","volume":"15","author":"Scala","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib34","first-page":"1","article-title":"Reduced economic disparity in biologics use for psoriasis after introducing the reducing copayment program","volume":"14","author":"Jung","year":"2024","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.eclinm.2026.104103_bib35","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.3390\/jcm12237234","article-title":"The influence of socioeconomic factors on access to biologics in psoriasis","volume":"12","author":"Norlin","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104103_bib36","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1111\/ijd.17377","article-title":"Frequency of use and annual costs of biological therapy for psoriasis in Colombia in 2019","volume":"63","author":"Fern\u00e1ndez-\u00c1vila","year":"2024","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104103_bib37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.abd.2023.04.006","article-title":"Unmet needs in the management of psoriasis in Latin America: a systematic review","volume":"99","author":"Ossanai Schoenardie","year":"2024","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.eclinm.2026.104103_bib38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.vhri.2022.12.001","article-title":"Economic evaluation of selected interleukin inhibitors versus methotrexate for moderate-to-severe plaque psoriasis, from the Philippine payer perspective","volume":"34","author":"Kimwell","year":"2023","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104103_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/JPDS.JPDS_40_24","article-title":"Real-world evidence from a cluster survey of patients guided by multi-center dermatologists toward the Philippine Psoriasis Registry","volume":"33","author":"Verallo-Rowell","year":"2024","journal-title":"J Philippine Dermatol Soc"},{"key":"10.1016\/j.eclinm.2026.104103_bib40","first-page":"12","article-title":"Indonesian clinical practice guidelines for systemic and biologic agents for adults with plaque psoriasis","volume":"5","author":"Novianto","year":"2021","journal-title":"J Gen Proc Dermatol Venereol Indonesia"},{"key":"10.1016\/j.eclinm.2026.104103_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/ejdv.ejdv_9_22","article-title":"Clinicodemographic and laboratory features of 200 Egyptian psoriatic patients","volume":"43","author":"Aboeldahab","year":"2023","journal-title":"Egypt J Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.eclinm.2026.104103_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260243","article-title":"Management practice, quality of life and associated factors in psoriasis patients attending a dermatological center in Ethiopia","volume":"16","author":"Kumsa","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2026.104103_bib43","series-title":"25th Expert Committee on selection and use of essential medicines","year":"2025"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104103_bib44","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"issue":"13","key":"10.1016\/j.eclinm.2026.104103_bib45","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.3390\/jcm13133713","article-title":"Basic susceptibility of patients with psoriasis under systemic therapy for respiratory infections: data from the German psoriasis registry PsoBest","volume":"13","author":"Stephan","year":"2024","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.eclinm.2026.104103_bib46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40266-022-00961-y","article-title":"Drug survival, safety, and effectiveness of biologics in older patients with psoriasis: a comparison with younger Patients\u2014A BioCAPTURE registry study","volume":"39","author":"ter Haar","year":"2022","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.eclinm.2026.104103_bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s13555-021-00499-8","article-title":"Real-world evidence from more than 1000 patients treated with adalimumab for moderate-to-severe psoriasis in the Czech Republic","volume":"11","author":"Kojanova","year":"2021","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaad.2025.03.018","article-title":"Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: a multicenter, randomized, phase III study","volume":"93","author":"Xia","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/14712598.2020.1684472","article-title":"Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience","volume":"20","author":"Galluzzo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104103_bib50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2133.2011.10778.x","article-title":"Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients","volume":"166","author":"Norlin","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12955-017-0721-x","article-title":"How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden","volume":"15","author":"Geale","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.eclinm.2026.104103_bib52","series-title":"Official exchange rate (LCU per US$, period average) | data","year":"2025"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104103_bib53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ad.2015.10.005","article-title":"Methotrexate in moderate to severe psoriasis: review of the literature and expert recommendations","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.eclinm.2026.104103_bib54","series-title":"International medical products price guide","year":"2016"},{"key":"10.1016\/j.eclinm.2026.104103_bib55","series-title":"Health products policy and standards","year":"2025"},{"key":"10.1016\/j.eclinm.2026.104103_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med Drug Discov"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib57","article-title":"Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors","volume":"27","author":"San-Juan-Rodriguez","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/24755303231212154","article-title":"Biosimilars in dermatology review","volume":"9","author":"Baker","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.eclinm.2026.104103_bib59","series-title":"The impact of biosimilar competition in Europe","volume":"vol. 1","author":"Troein","year":"2025"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40545-023-00581-w","article-title":"Maximizing the benefits of using biosimilars in Egypt","volume":"16","author":"Fasseeh","year":"2023","journal-title":"J Pharm Policy Pract"},{"key":"10.1016\/j.eclinm.2026.104103_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104103_bib62","first-page":"600","article-title":"Sustaining competition for biosimilars on the pharmacy benefit: use it or lose it","volume":"30","author":"Mehr","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"26","key":"10.1016\/j.eclinm.2026.104103_bib63","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043010","article-title":"Comparative real-world retention rate and safety of biosimilar IBI303 versus Humira in ankylosing spondylitis: a retrospective study","volume":"104","author":"Cheng","year":"2025","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104103_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25259\/IJDVL_1384_2024","article-title":"Methotrexate dosage and laboratory monitoring in patients with psoriasis and psoriatic arthritis: a retrospective analysis of prescription patterns and financial impact in dermatology and rheumatology settings","volume":"91","author":"Anjaneyan","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.eclinm.2026.104103_bib65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/PTT.S531836","article-title":"Utilization and costs of laboratory monitoring in biological and non-biological psoriasis treatment \u2013 a large-scale claims data analysis","volume":"15","author":"Wagner","year":"2025","journal-title":"Psoriasis Targets Ther"},{"issue":"8","key":"10.1016\/j.eclinm.2026.104103_bib66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/13696998.2018.1472097","article-title":"Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity","volume":"21","author":"Murage","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.eclinm.2026.104103_bib67","series-title":"Final appraisal determination Adalimumab for the treatment of adults with psoriasis","year":"2008"},{"key":"10.1016\/j.eclinm.2026.104103_bib68","series-title":"Ustekinumab for the treatment of adults with moderate to severe psoriasis","year":"2008"},{"issue":"5","key":"10.1016\/j.eclinm.2026.104103_bib69","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/ijd.14864","article-title":"Global burden of psoriasis \u2013 comparison of regional and global epidemiology, 1990 to 2017","volume":"59","author":"AlQassimi","year":"2020","journal-title":"Int J Dermatol"},{"issue":"Suppl 3","key":"10.1016\/j.eclinm.2026.104103_bib70","article-title":"Global epidemiology of psoriasis: global Psoriasis Atlas 2024 update [Abstract]","volume":"191","author":"Asadullah","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.eclinm.2026.104103_bib71","series-title":"SDG 3.8.2 catastrophic health spending (and related indicators)","year":"2025"},{"key":"10.1016\/j.eclinm.2026.104103_bib72","series-title":"Assessing the impact of childhood and adolescent chronic plaque psoriasis on parents\/caregivers using the Family Dermatology Life Quality Index (FDLQI): a cross-sectional study","author":"Bhandari","year":"2025"},{"issue":"3","key":"10.1016\/j.eclinm.2026.104103_bib73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.abd.2020.09.004","article-title":"Out-of-pocket costs for patients with psoriasis in an outpatient dermatology referral service","volume":"96","author":"Maya-Rico","year":"2021","journal-title":"An Bras Dermatol"},{"issue":"10","key":"10.1016\/j.eclinm.2026.104103_bib74","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jamadermatol.2021.3616","article-title":"Out-of-pocket costs of specialty medications for psoriasis and psoriatic arthritis treatment in the Medicare population","volume":"157","author":"Pourali","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.eclinm.2026.104103_bib75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0272989X15583266","article-title":"Distributional cost-effectiveness analysis: a tutorial","volume":"36","author":"Asaria","year":"2015","journal-title":"Med Decis Mak"},{"issue":"10067","key":"10.1016\/j.eclinm.2026.104103_bib76","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(16)31599-9","article-title":"Essential medicines for universal health coverage","volume":"389","author":"Wirtz","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eclinm.2026.104103_bib77","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","article-title":"Evaluating the economic burden of psoriasis in the United States","volume":"72","author":"Vanderpuye-Orgle","year":"2015","journal-title":"J Am Acad Dermatol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026003561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:30:08Z","timestamp":1787560208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026003561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":77,"alternative-id":["S2589537026003561"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104103","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global health and economic impact of expanding the WHO essential medicines list for psoriasis: a health economic modelling study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104103"}}